JUBLPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 26/100 — Quality 40 · Valuation 8 · Growth 8 · Momentum 52
| Share price | ₹1,023.85 |
| Market cap | ₹13,730 Cr |
| P/E ratio | 31.8 |
| P/B ratio | 2.1 |
| ROE | 15.8% |
| ROCE | 11.3% |
| Dividend yield | 0.58% |
| Book value | ₹415.87 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹8,280 Cr | ₹398 Cr | 15.0% |
| 2025 | ₹7,234 Cr | ₹836 Cr | 16.0% |
| 2024 | ₹6,703 Cr | ₹73 Cr | 13.0% |
| 2023 | ₹6,282 Cr | ₹-65 Cr | 12.0% |
| 2022 | ₹6,130 Cr | ₹413 Cr | 19.0% |
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunother